Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biohaven Pharmaceuticals, Inc.
Age
40–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Diagnosis of probable or possible MSA according to consensus clinical criteria (Gilman et al 2008), including participants with MSA of either subtype (MSA-P or MSA-C).
2. Able to ambulate without the assistance of another person, defined as the ability to take at least 10 steps. Use of assistive devices (e.g., walker or cane) is allowed.
3. Anticipated survival of at least 3 years at the time of Screening, as judged by the Investigator.
You may not be if
1. Any condition that would interfere with the participant's ability to comply with study instructions, place the participant at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator.
2. Diagnosis of neurological disorders, other than MSA.
Clareo Health | Study of BHV-3241 in Participants With Multiple System Atrophy
